Detection of p16 abnormalities in early-stage non-small cell lung cancer

Folia Histochemica et Cytobiologica

Volumn 39, Issue SUPPL. 2, 2001, Pages 30-32

  Niklinska, W ^a   Chyczewski, L ^a   Laudanski, J ^a   Chyczewska, E ^a   Niklinski, J ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diagnosis; Lung cancer; P16; Prognosis

Indexed keywords

MOLECULAR MARKER; PROTEIN P16;

CANCER CLASSIFICATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL EXAMINATION; CONFERENCE PAPER; EARLY CANCER; FEMALE; GENDER; GENE ACTIVATION; HAZARD ASSESSMENT; HISTOPATHOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POINT MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN METHYLATION; SEQUENCE ANALYSIS;

EID: 0035689003     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (14)

1. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis
2. Molecular pathogenesis of lung cancer
3. Mechanisms of p16INK4A inactivation in non-small cell lung cancers
4. Hypermethylation of tumor suppressor genes in cancer
5. Methylation-specific PCR: A novel PCR assay for methylation status of CpG island
6. p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung
7. Changes in expression of pRb, p16 and cyclin D1 in non-small cell lung cancer: An immunohistochemical study
8. Revisions in the international system for staging lung cancer
9. New molecular approaches to lung cancer: Biological and clinical implications of P53, P16 and K-ras studies
10. The p16INK4a/CDKN2A tumor suppressor and its relatives
11. Molecular abnormalities in lung cancer
12. Genetic, epigenetic, dysgenetic, and non-genetic mechanisms in tumorigenesis
13. Prognostic value of the immunohistochemical detection of p16INK4 expression in non-small cell lung carcinoma
14. Hypermethylation of the dead-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small lung cancer